Please login to the form below

Not currently logged in
Email:
Password:

Lumykras

This page shows the latest Lumykras news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending Amgen’s Lumykras (sotorasib) for treatment use within the Cancer Drugs Fund. ... The CMA for Lumykras is based on clinical evidence from the

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...